Coeptis Therapeutics’ Dave Mehalick on the disruptive potential of SNAP-CAR technology for autoimmune diseases

In an insightful interview with Tracy Weslosky, Dave Mehalick, Chairman, President, and CEO of Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), delves into the company’s groundbreaking work in cell therapy, particularly against the backdrop of the “tripledemic” of influenza, COVID-19, and respiratory syncytial virus (RSV). Mehalick highlights the success of their phase one clinical trial, which focused on treating hospitalized COVID-19 patients with off-the-shelf natural killer cells, leading to every patient being discharged fully healthy. He emphasizes the potential of this therapy beyond COVID-19, aiming to tackle a wide range of respiratory diseases in future phase two clinical trials. Mehalick provides an overview of cell therapy’s competitive landscape, explaining how Coeptis’s approach strengthens patients’ immune systems against diseases by using manufactured cells, not derived from the patients themselves. This innovation could revolutionize the treatment of various diseases, particularly respiratory ones. Additionally, Mehalick discusses the company’s recent news, including a partnership with the University of Pittsburgh to expand the use of SNAP-CAR T and SNAP-CAR NK cells beyond oncology to autoimmune diseases. This expansion is significant, as it leverages the company’s universal cell structure technology, potentially offering a simpler and more cost-effective treatment for autoimmune diseases and cancers. Mehalick outlines the potential of SNAP-CAR technology to transform the treatment landscape for autoimmune diseases, offering a more accessible and affordable alternative to current CAR-T therapies. This approach could significantly reduce treatment costs and time, making advanced therapies available to a broader patient population. The interview touches on the broader implications of Coeptis’s cell therapy platform, highlighting its potential to disrupt traditional medical treatment modalities globally.